Clinical trials: Bacterial Transmission
Gonorrhea of Pharynx, Gonorrhea
Aztreonam for Pharyngeal Gonorrhea
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats.
- Trial name
- NCT03867734
- Testing
- Aztreonam
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Washington
Tuberculosis, Latent Tuberculosis
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
The Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial) study will be a three-arm, open-label, parallel, randomized trial.
- Conditions
- Tuberculosis, Latent Tuberculosis, HIV/AIDS
- Trial name
- NCT03934931
- Testing
- Streamlined weekly DOT visits, Weekly DOT visit reminders, Cost reimbursement DOT
- Where
- Uganda
- Volunteers
- 1,656 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Syphilis
Lumbar Puncture and Syphilis Outcome
Treponema pallidum, the bacterium that causes syphilis, invades the central nervous system in about 40% of patients with syphilis. This happens early after infection.
- Trial name
- NCT02031146
- Testing
- Lumbar puncture
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Washington
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Syphilis
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S.
- Trial name
- EHPOC (NCT04793750)
- Testing
- Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis, HIV Infections
Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
This is a randomized, blinded, two-arm comparative trial of continued versus limited isoniazid (INH) tuberculosis (TB) preventive therapy in HIV-infected adults in Gaborone and Francistown, Botswana.
- Trial name
- NCT00164281
- Testing
- Isoniazid
- Where
- Botswana
- Volunteers
- 1,995 people
- Sponsor
- Centers for Disease Control and Prevention
Infection, Human Immunodeficiency Virus, HIV Infections
Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
This is a Phase I, single-center, open-label, fixed-sequence, 2-period crossover study in healthy adults to evaluate the effect of oral rifabutin (RBT) 300 milligram (mg) on the pharmacokinetics of oral cabotegravir (CAB) 30…
- Trial name
- NCT03149848
- Testing
- Cabotegravir, Rifabutin
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Gonococcal Infection
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
This is a Phase 1, interventional, non-randomized, experimental infection model study in healthy adult males (N=up to 25) between the ages of 18-35 at study enrollment.
- Trial name
- NCT04870138
- Testing
- Azithromycin, Ceftriaxone, Ciprofloxacin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhea, Chlamydia
Adolescent Sexually Transmitted Infection Screening in the Emergency Department
Sexually transmitted infections (STIs) are highly prevalent among adolescents. Clinical practices related to screening, diagnosis, treatment, and prevention of STIs among adolescents are suboptimal.
- Trial name
- STI (NCT03715335)
- Testing
- Targeted STI Screening, Universally Offered STI Screening
- Where
- 5 sites in United States
- Volunteers
- 98,413 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Gonorrhoea
Efficacy of Combination Therapies for Gonorrhea Treatment
The purpose of this study is to learn how to better treat gonorrhea infections. Gonorrhea is a sexually transmitted disease (STD) that is usually cured with a single antibiotic.
- Trial name
- NCT00926796
- Testing
- Azithromycin, Gentamicin, Gemifloxacin
- Where
- 5 sites in United States
- Volunteers
- 614 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, Gonorrhea Male
Expedited Partner Therapy and the HIV Prevention Cascade
The HIV epidemic in Peru remains concentrated in the subpopulation of men who have sex with men (MSM), where the prevalence of disease has been estimated between 10-22% in recent epidemiologic surveys.
- Conditions
- HIV-1-infection, Gonorrhea Male, Chlamydia, Partner Communication
- Trial name
- EPT and MSM (NCT04553211)
- Testing
- EPT
- Where
- Peru
- Volunteers
- 663 people
- Sponsor
- University of California, Los Angeles
Syphilis, Early Syphilis
Cefixime for Alternative Syphilis Treatment
The goal of the study is to evaluate the efficacy of oral cefixime as an alternative treatment for syphilis infection. One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema Pallidum Particle…
- Trial name
- NCT03660488
- Testing
- Cefixime 400 milligram Oral Capsule [Suprax], Benzathine Penicillin G
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of California, Los Angeles
Tuberculosis, HIV/AIDS
Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)
The Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) will examine the safety and tolerability of, and adherence to, 6 months of daily INH (6H) in 300 TB and HIV-infected persons (200 drinkers and 100 non-drinkers)…
- Conditions
- Tuberculosis, HIV/AIDS, Alcohol Abuse
- Trial name
- ADEPTT (NCT03302299)
- Testing
- Isoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
- Where
- Uganda
- Volunteers
- 302 people
- Sponsor
- University of California, San Francisco
Tuberculosis, HIV Infections
Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)
This is a phase II, proof of concept, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy against TB disease, safety, and immunogenicity of MVA85A/AERAS-485 in healthy, HIV-infected adults.
- Trial name
- NCT01151189
- Testing
- MVA85A/AERAS-485
- Where
- 2 sites in Senegal, South Africa
- Volunteers
- 650 people
- Sponsor
- Aeras
Gonorrhoea
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae…
- Trial name
- NCT04722003
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT)…
- Conditions
- Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
- Trial name
- NCT06369220
- Testing
- cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice
- Where
- 4 sites in United States
- Volunteers
- 331 people
- Sponsor
- Hoffmann-La Roche
Tuberculosis, AIDS-related Complex
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
- Trial name
- NCT00201123
- Testing
- Aerosol Interferon-Gamma, Subcutaneous interferon-gamma
- Where
- 2 sites in United States, South Africa
- Volunteers
- 89 people
- Sponsor
- NYU Langone Health
Bacterial Infections
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.
- Trial name
- NCT00998309
- Testing
- Azithromycin SR
- Volunteers
- 502 people
- Sponsor
- Pfizer
HIV/AIDS, Tuberculosis, Pulmonary
INSTI's For The Management of HIV-associated TB
This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected…
- Trial name
- INSIGHT (NCT04734652)
- Testing
- Biktarvy®, TLD- fixed-drug combination single tablet
- Where
- South Africa
- Volunteers
- 122 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV/AIDS, Tuberculosis
Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa
Background: In 2023, the South African Department of Health introduced targeted universal TB testing (TUTT) at antiretroviral therapy (ART) initiation (irrespective of the presence of TB symptoms).
- Trial name
- TUTT-PT (NCT06739915)
- Testing
- TUTT-PT Intervention
- Where
- South Africa
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University